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Sultanate of OmanAbstract Background and objective: Elevated LDL (Low Density Lipoprotein) cholesterol is a
major cause of Coronary Heart Disease (CHD) and LDL lowering therapy reduces the risk for
CHD. The study was conducted with the aim of assessing the prescribing pattern of statins based
on cardiovascular risk factor category, pattern of lipid monitoring followed among the patients and
extent of attainment of goal Low Density Lipoprotein (LDL-C) observed among the patients.
Methods: A group of patient ﬁles (among those on statin agent during the year 2011) from the
Department of Medicine in Nizwa Hospital were selected for targeted evaluation on the risk factor
status of patients and efﬁcacy of statins in attaining goal lipid levels. Goal LDL-C levels were esti-
mated for each patient depending on their risk factor status. Subsequent follow ups of the patients
were reviewed from the patient ﬁles and accordingly the attainment and maintenance of goal-LDL-C
in the patients were evaluated. Results: A total of 183 patients were identiﬁed. Mean age of the
evaluated patients was 63.6 ± 11.58 years. Evaluating the status of patients on the presence of risk
factors, majority (63.9%) of them had presence of CHD. Simvastatin was the most commonly used
agent and titration of dose was done in only 3.3% of patients. Mean LDL-C level of the patient
before initiation of treatment was 3.74 ± 1.9 mmol/L. Only in 59 (32.2 %) of the total evaluated
183 patients, there was evidence of attaining goal-LDL-C levels. Among them, there was evidencel Mouz,
372 J. Jose et al.of maintenance of goal LDL-C in 16 (27.1%) of the patients. Conclusion: Statins were used less fre-
quently for primary prevention of CHD. Absence of lipid monitoring; base line and follow up in a
good number of patients as well as lack of dose titration among the patients were observed. Impor-
tance of adequate lipid monitoring and follow up to ensure attainment of goal LDL-C needs to be
stressed to serve the objective of use of statins; primary and secondary prevention of CHD.
ª 2014 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Research from animal studies, epidemiological studies and
other shows that elevated LDL (Low Density Lipoprotein)
cholesterol is a major cause of Coronary Heart Disease
(CHD). LDL lowering therapy reduces the risk for CHD
(Expert Panel of Detection, 2001). Guidelines recommend stat-
ins to be used for primary prevention in individuals at high risk
independent of their cholesterol levels as well as for those with
moderate and low risks with cholesterol levels above the
threshold (Genest et al., 2009). The third report of the expert
panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III, or ATP III)
constitutes the National Cholesterol Education Program
(NCEP) updated clinical guidelines for cholesterol testing
and management. Primary goals of therapy and cut points
for initiating treatment with statins are stated in terms of
LDL. ATP III guidelines were formed based on large, random-
ized, and controlled clinical trials (RCTs) (Expert Panel of
Detection, 2001). Since the publication of ATP III, 5 major
clinical trials (Heart Protection Study Collaborative Group,
2002; Shepherd et al., 2002; ALLHAT, 2002; Sever et al.,
2003; Cannon et al., 2004) of statin with clinical endpoints
were published which resulted in the update on the guidelines
(Grundy et al., 2004). Those trials conﬁrmed the beneﬁt of
cholesterol lowering therapy in high risk patients and support
the ATP III treatment goal of LDL-C <100 mg/dl (Grundy
et al., 2004). The American Diabetes Association (ADA) stan-
dards of care for diabetes state that statin therapy should be
initiated in individuals with diabetes and other cardiovascular
risk factors with a target LDL cholesterol of 100 mg/dl (Eldor
and Raz, 2009). Statins can lower LDL cholesterol concentra-
tion by an average of 1.8 mmol/L which reduces the risk of
Ischemic Heart Disease (IHD) events by about 60% and
stroke by 17% (Law et al., 2003).
Previous studies have suggested that only about 1/3 of
patients treated with statins actually reach the goals in primary
prevention and in secondary prevention (Pearson et al., 2000).
At times statins are underprescribed even among patients diag-
nosed with CHD (Condliffe et al., 2010). In the study con-
ducted by Berthold to assess the patterns and predictors of
statin prescription in patients with type 2 diabetes, it was
reported that the majority of patients with type 2 diabetes
are not receiving statins. Further, prescription was signiﬁcantly
higher in the secondary compared to the primary prevention
group (38.1% vs. 18.5%, respectively) (Berthold et al., 2009).
In the retrospective chart review conducted by Al-Siyabi
et al. in Sultan Qaboos University Hospital, Oman in 2008
among 161 patients, it was observed that more than half of
the high risk patients were not at the target LDL-C goalswhich place them at a continuous risk of CHD (Al-Siyabi
et al., 2010).
Even though statins are prescribed quite frequently in
regular practice in Oman, the extent to which the efﬁcacy
of these drugs in achieving the goals of therapy (achieving
target LDL-C goals) is monitored is questionable. Inﬂuence
of pharmacogenomics on the efﬁcacy of statins is docu-
mented (Mangravite et al., 2008) and hence a variation in
the effect of statins in achieving the goal LDL-C is plausible
depending on the genetic factors of the population. There
are only limited studies conducted in Oman and in the
region which tried to evaluate the efﬁcacy or pattern of stat-
ins in achieving goal-LDL-C (Al-Siyabi et al., 2010). Moni-
toring of the goal LDL-C could greatly inﬂuence the efﬁcacy
of the statins in attaining the endpoints with regard to pri-
mary and secondary prevention of cardiovascular events.
Hence this study was conducted with the aim of assessing
the prescribing pattern of statins based on risk factor cate-
gory, pattern of lipid monitoring followed among patients
and extent of attainment of goal LDL-C observed among
the patients. Nizwa Hospital is a 302 bed regional hospital
in Al Dakhliya Governorate in Sultanate of Oman. The
present study was conducted in the Department of Medicine
of Nizwa Hospital.2. Methods
The study received approval from the Regional Research and
Ethics Committee of Al Dakhliya Governorate, Ministry of
Health, Sultanate of Oman. A group of patient ﬁles (among
those on statin agent during the year 2011) in the Department
of Medicine of Nizwa Hospital was selected for targeted
evaluation on the risk factor status of patients and efﬁcacy
of statins in attaining goal lipid levels. Details required for
the study purpose were obtained from the patient ﬁle which
included details on the statin agent used, lipid proﬁle (before
initiation of statin), assessment of the patients risk status based
on the presence of CHD or CHD risk equivalents, and identi-
ﬁcation of major risk factors. In those required cases, the
Framingham risk score was calculated and the risk score was
categorized accordingly (Grundy et al., 2004).
Accordingly, patients were categorized into the following
risk categories; Category 1 (CHD and CHD risk equivalents),
Category 2 (multiple (2+) risk factors) and Category 3 (0–1
risk factor). Consequently the goal LDL-C was estimated
for each patient (Grundy et al., 2004). For each case, details
on the statin agent used and dose titration were obtained
and evaluated. Subsequent follow ups of the patients were
reviewed from the patient ﬁles regarding the lipid proﬁles
Table 2 Status on presence of risk factors.
Parameters No (%)
Presence of aCHD
Yes 117 (63.9)
No 66 (36.1)
Presence of CHD equivalent
Yes 52 (28.4)
No 131 (72.6)
Presence of diabetes mellitus
Yes 28 (15.3)
No 155 (84.7)
Risk category of patients
Category 1 169 (92.3)
(CHD and CHD risk equivalents)
Category 2 6 (3.3)
(Multiple (2+) risk factors)
Category 3 8 (4.4)
(0–1 risk factor)
a Coronary Heart Disease.
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patients were evaluated. Details on the maintenance of
attained goal LDL-C were assessed. During the patient follow
up period, if there was any change in risk category of the
patients, accordingly the goal-LDL-C was modiﬁed for the
purpose of the evaluation of the attainment of the same.
2.1. Statistical analysis
Descriptive statistical analysis was done for many of the
parameters. Relationship between risk factor status and lipid
proﬁle was done by Mann Whitney U test and Kruskal Wal-
lis test depending on the number of comparative groups.
Additionally, the relationship between the patient demo-
graphics (age group and gender) with the presence of
CHD and CHD equivalent was evaluated using Chi- Square
analysis. P value of <0.05 was considered to be statistically
signiﬁcant. SPSS version 15 was used for the statistical
analysis.
3. Results
A retrospective review of the medical records was done to
identify patients on any statin agent during the year 2011
(the study population) in Nizwa Hospital. Inclusion criteria
for the study included data of patients who visited the outpa-
tient department or were admitted as inpatients in the Depart-
ment of Medicine and were receiving any statins in their
medication list. A total of 183 patients were selected from
the total of 927 patients on a statin agent.
3.1. Patient demographics
Demographics of the patients are represented in Table 1. A
higher number of patients were in the age group of 61–75
(46.4%) compared to other groups. Mean age of the evaluated
patients was 63.6 ± 11.58 years.
3.2. Status on presence of risk factors
Evaluating the status of the patients on the presence of risk
factors, majority (63.9%) of them had the presence of CHD,
Table 2. CHD equivalents such as other clinical forms of ath-
erosclerotic disease and diabetes were present only in 28.4% of
them. Diabetes mellitus was a diagnosis in 15.3% of evaluated
patients. Among the 13 patients in whom the Framingham
Risk Score was estimated, the average risk score was 24.07.Table 1 Demographics of patients.
Parameters No. (%)
Age group
30–45 11 (6)
46–60 62 (33.9)
61–75 85 (46.4)
>75 25 (13.7)
Gender
Male 99 (54.1)
Female 84 (45.9)Identifying the risk category of the patients, a vast majority
(92.3%) of them belonged to category 1 (CHD and CHD risk
equivalents) as represented in Table 2.
3.3. Relationship between patient demographics and risk status
The relationship between patient demographics and risk status
of the patients is represented in Table 3. Accordingly, the sta-
tus of the presence of CHD or CHD equivalent did not differ
signiﬁcantly based on the age group and gender of patients.
3.4. Details on statin agent used
Assessing the details on statin agent used among the patients,
simvastatin was the most commonly used agent (86.3%) fol-
lowed by atorvastatin (12.6%); Table 4. In vast majority
(96.2%) of the cases, the initiating dose was 20 mg. Titration
of dose was done in only 3.3% of patients. The statin agent
was changed in 12% of the evaluated patients.
3.5. Details on lipid monitoring done and attainment of goal
LDL-C
Details on lipid monitoring done among the patients are repre-
sented in Table 5. Only in 65.6% of patients lipid proﬁle was
obtained before initiation of statin agent. Mean/Median lipid
levels among the patients are represented in Table 5.
Only in 93 patients there was a follow up lipid proﬁle done
during subsequent visits of patients. In 32.2% of the total eval-
uated 183 patients, there was evidence of attaining goal-LDL-
C levels, Table 6. Among these 59 patients, there was evidence
of maintenance of goal LDL-C in 16 (27.1%) of patients.
4. Discussion
This targeted evaluation among selected patients on statin
agent was done to evaluate the risk factor status of patients,
lipid monitoring pattern and attainment of goal LDL-Cs.
Table 3 Patient demographics vs. risk status.
Parameters Presence of CHD p value Presence of CHD equivalent p value
Age group Yes No Yes No
No. (%) No. (%) No. (%) No. (%)
30–45 3 (27.2) 8 (72.7) p= 0.075 6 (54.5) 5(45.6) p= 0.316
46–60 41 (66.1) 21(33.9) 17 (27.4) 45 (72.5)
61–75 57 (67.1) 28 (22.9) 24 (28.3) 61 (71.7)
>75 16 (64) 9 (36) 7 (28) 18 (72)
Gender
Male 62 (62.6) 37 (37.4) p= 0.602 33 (33.3) 66 (66.7) p= 0.349
Female 55 (65.5) 29 (34.5) 22 (26.2) 62 (73.8)
Table 4 Details on statin agent used.
Parameters No. (%)
Statin agent
Simvastatin 158 (86.3)
Atorvastatin 23 (12.6)
Fluvastatin 2 (1.1)
Dose (mg)
20 176 (96.2)
40 5 (2.7)
Others 2 (1.1)
Dose change
Yes 6 (3.3)
No 177 (96.7)
Drug change
Yes 22 (12)
No 161 (88)
Table 6 Attainment of Goal LDL-C levels.
Goal LDL-C attained No. (%)
Yes 59 (32.2)
No 34 (18.6)
Cannot be assessed 90 (49.1)
374 J. Jose et al.Among the 183 patients selected for the targeted evaluation, a
higher number of them were in the age group of 61–75 and
were males. A similar result was obtained in the study con-
ducted by Sreedevi et al. (2011). Current guidelines recom-
mend the use of statins to reduce LDL-C to appropriate
targets and clearly state that older age should not be a barrier
to treatment (Expert Panel of Detection, 2001; Grundy et al.,
2004; Wenger and Lewis, 2010). It is reported that despite evi-
dence demonstrating clear beneﬁt with statin therapy in older
individuals, they are usually undertreated (Wenger and Lewis,
2010). Majority of the patients had CHD as a diagnosis in
them. Accordingly secondary prevention was the most com-
mon indication for use. Similarly in the study conducted by
Berthold et al., prescriptions for statins were signiﬁcantlyTable 5 Lipid monitoring and results.
Lipid proﬁle done before initiation of statin Lipid levels (M
Yes No aTC
125 (65.6) 58 (34.4) 5.75 (eIQR 2)
a Total cholesterol.
b Low density lipoprotein-cholesterol.
c High density lipoprotein-cholesterol.
d Triglycerides.
e Interquartile range.higher for secondary prevention than for primary (Berthold
et al., 2009).
Diabetes mellitus was a diagnosis in approximately 15% of
the patients. In the study conducted among 51,640 patients
with type 2 diabetes in a German diabetes registry, it was
observed that 34% had established atherosclerotic disease
and 25.5% received a statin. Authors reported that majority
of patients with diabetes mellitus are not receiving statins.
Identifying the risk category of the patients in our study, vast
majority (92.3%) of them belonged to category 1 (CHD and
CHD risk equivalents). Prevalence of CHD did not differ sig-
niﬁcantly based on age group or gender. But, the prevalence
was higher in the age groups of 46 and above. CHD is reported
as the principal cause of mortality in elderly and 80% of deaths
due to CHD or stroke occur in patients above the age of
65 years of age (Wenger and Lewis, 2010).
Simvastatin was the most commonly prescribed agent
which was following the drug availability pattern of statin
agent in the Ministry of Health, more than inﬂuenced by the
choice of agents as practiced by prescribers. Atorvastatin
was the most commonly used agent in the studies conducted
in Indian population (Sreedevi et al., 2011; PV and Sen,
2012). The most commonly used agent, simvastatin was started
on the minimum dose of 20 mg and surprisingly no doseean/Median)
bLDL-C cHDL-C dTG
3.74 (SD± 1.9) 1.16 (IQR 0.46) 1.47 (IQR 1.19)
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explained to some extent to the fact that in 93 of the 183 eval-
uated patients, no follow up lipid proﬁle monitoring was done.
According to available details, it was observed that lipid
proﬁle before initiation of statin was not obtained in 34.4%
of the patients. The probable reason is that statin agent was
prescribed mainly for secondary prevention irrespective of
the baseline LDL-C levels. But, there is a need to obtain these
base line levels in all the patients to monitor the attainment of
goal LDL-C concentration after initiation of treatment.
Accordingly, the lack of subsequent monitoring of lipid levels
in almost 50% of the patients is a concern taking into consid-
eration the need of monitoring the attainment of lowering of
lipid levels among the patients. In the meta analysis conducted
by Law et al. aimed at quantifying the effect of statins on
LDL-C levels in IHD and stroke, it was reported that statins
can lower LDL-C concentration by an average of 1.8 mmol/
L which reduces the risk of IHD events by 60% and stroke
by 17% (Law et al., 2003).
Mean LDL-C of the patients before initiation of the statin
agent was 3.74 ± 1.9 mmol/L. These values were lower than
the pretreatment concentration of LDL-C reported in the
meta-analysis by Law et al. which was 4.8 mmol/L (Law
et al., 2003).
4.1. Limitations
The study had its own limitations. As it is based on retrospec-
tive data like any other study relying on already available data,
inherent drawbacks of incomplete or inconsistent documenta-
tion could be expected. As vast majority of the patients were
only on simvastatin, a reliable data on the effect of other
agents could not be assessed. Further, only in 50% of the
patients, follow up lipid proﬁle was available and accordingly
attainment of goal LDL-C could not be assessed. Further,
since the follow up lipid monitoring was done at different time
durations after initiation of statin in the patients, generalized
quantiﬁcation of the time taken for reduction in lipid levels
among the patients could not be done effectively.5. Conclusion
The study was able to provide certain useful information on
the prescribing pattern of statins based on risk factor category,
pattern of lipid monitoring followed among the patients and
extent of attainment of goal LDL-C observed among the
patients. Considering the risk factor category of statin users,
it was most commonly used for category 1 patients (CHD
and CHD equivalents) and secondary prevention of CHD. It
was used for primary prevention less frequently and was used
in patients with diabetes mellitus also less commonly. Absence
of lipid monitoring; base line and follow up in a good number
of patients as well as lack of dose titration among the patients
were observed. Attaining of goal- LDL-C among the statin
users is of prime importance and the evidence of the same
was observed only in one third of the evaluated patients. Ade-
quate lipid monitoring and follow up to ensure attainment of
goal LDL-C will serve the purpose of statin use; primary
and secondary prevention of CHD.Acknowledgments
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